Insider Trading Activity Sorrento Therapeutics Inc (NASDAQ:SRNE) – Major Shareholder Bought 550,000 shares of Stock

69

Insider Trading Activity For Sorrento Therapeutics Inc (NASDAQ:SRNE)

Abg Management Ltd , Major Shareholder of Sorrento Therapeutics Inc (NASDAQ:SRNE) reportedly Bought 550,000 shares of the company’s stock at an average price of 2 for a total transaction amount of $1,100,000.00 SEC Form

Insider Trading History For Sorrento Therapeutics Inc (NASDAQ:SRNE)

  • On 11/7/2013 Opko Health, Inc., Major Shareholder, sold 120,380 with an average share price of $9.03 per share and the total transaction amounting to $1,087,031.40. View SEC Filing
  • On 11/8/2013 Opko Health, Inc., Major Shareholder, sold 2,000 with an average share price of $8.75 per share and the total transaction amounting to $17,500.00. View SEC Filing
  • On 11/13/2013 Opko Health, Inc., Major Shareholder, sold 13,457 with an average share price of $8.75 per share and the total transaction amounting to $117,748.75. View SEC Filing
  • On 11/14/2013 Opko Health, Inc., Major Shareholder, sold 1,900 with an average share price of $8.75 per share and the total transaction amounting to $16,625.00. View SEC Filing
  • On 11/15/2013 Opko Health, Inc., Major Shareholder, sold 2,710 with an average share price of $8.75 per share and the total transaction amounting to $23,712.50. View SEC Filing
  • On 11/19/2013 Jaisim Shah, Director, bought 1,000 with an average share price of $9.00 per share and the total transaction amounting to $9,000.00. View SEC Filing
  • On 11/19/2013 Henry Ji, CEO, bought 2,000 with an average share price of $8.59 per share and the total transaction amounting to $17,180.00. View SEC Filing
  • Analyst Ratings For Sorrento Therapeutics Inc (NASDAQ:SRNE)
    These are 4 Buy Ratings .
    The current consensus rating for Sorrento Therapeutics Inc (NASDAQ:SRNE) is Buy (Score: 3.00) with a consensus target price of $15.00 , a potential (782.35% upside)

    Analyst Ratings History For Sorrento Therapeutics Inc (NASDAQ:SRNE)

    • On 8/3/2015 MLV & Co. Initiated Coverage of rating Buy with a price target of $34.00
    • On 12/7/2015 HC Wainwright Initiated Coverage of rating Buy with a price target of $45.00
    • On 7/17/2016 Rodman & Renshaw Reiterated Rating Buy
    • On 8/12/2016 Brean Capital Reiterated Rating Buy
    • On 11/2/2016 Roth Capital Set Price Target of rating Buy with a price target of $15.00
    • On 4/4/2017 FBR & Co Reiterated Rating Buy

    About Sorrento Therapeutics Inc (NASDAQ:SRNE)
    Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

    Recent Trading Activity for Sorrento Therapeutics Inc (NASDAQ:SRNE)
    Shares of Sorrento Therapeutics Inc closed the previous trading session at 1.83 up +0.12 7.35% with 2,529,480 shares trading hands.

    An ad to help with our costs